Mr Adam Rance
|Department||Department of Pathology (DSM)|
|Research summary||Androgen receoptor signalling in triple negative breast cancer|
Adam is currently pursuing a Master of Science Degree in the Molecular Oncology Group, supervised by Dr. Heather Cunliffe. He is investigating the role of Anrogen Receptor signaling in Triple Negative Breast Cancer (TNBC).
TNBC is a highly aggressive subtype of breast cancer diagnosed in 10-25% of patients. As TNBCs do not express clinically significant levels of the estrogen receptor (ER), the progesterone receptor (PgR) and human epidermal growth factor 2 receptor (HER2), treatments that target and disrupt these receptors are not useful for this subtype, leaving no established options for systemic therapy other than chemotherapy.
Recently, 20-25% of TNBCs have been defined as positive for the androgen receptor (AR), and early data from clinical trials in AR-positive metastatic TNBC suggest significant response to androgen signalling blockade. The molecular evidence necessary to predict response to AR signaling antagonism in TNBC, and the mechanism(s) by which AR promotes disease progression in this subtype remains elusive, and the motivation for Adam’s research.